---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-047402"
form_type: "8-K"
ticker: "ABBV"
cik: "0001551152"
company_name: "AbbVie Inc."
filed_at: "2025-05-13T23:59:59+00:00"
generated_at: "2026-05-21T15:37:30.027298+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# AbbVie appoints Thomas Falk (ex-Kimberly-Clark CEO) to board; Gonzalez, Tilton to retire July 1

## Summary
- Board expanded to 15; Thomas J. Falk (former Kimberly-Clark CEO) appointed as Class III director and to Audit Committee; deemed independent.
- Board to shrink to 13 upon retirement of Richard A. Gonzalez and Glenn F. Tilton effective July 1, 2025.
- Compensation Committee raised Robert A. Michael's 2025 annual bonus target to 165% of base salary for Chairman role.
- Shareholders ratified EY as auditor and approved say-on-pay; both management and stockholder proposals to eliminate supermajority voting failed.

## SEC filing metadata
- accession: 0001104659-25-047402
- form_type: 8-K
- ticker: ABBV
- cik: 0001551152
- company_name: AbbVie Inc.
- filed_at: 2025-05-13T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 5.02, 5.07
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1551152/000110465925047402/0001104659-25-047402-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1551152/000110465925047402/tm2513856d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-047402
- JSON: https://secwatch.observer/filing/0001104659-25-047402.json
- Plain text: https://secwatch.observer/filing/0001104659-25-047402.txt

## Key facts
- Executive change
  Richard A. Gonzalez departed as Director at AbbVie Inc..
  - Action: retire
  - Role: Director
  source text: The Board also determined that the size of the Board will decrease from fifteen directors to thirteen directors upon the retirement of Richard A. Gonzalez and Glenn F. Tilton from the Board, effective July 1, 2025.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1551152/000110465925047402/0001104659-25-047402-index.htm
- Executive change
  Glenn F. Tilton departed as Director at AbbVie Inc..
  - Action: retire
  - Role: Director
  source text: The Board also determined that the size of the Board will decrease from fifteen directors to thirteen directors upon the retirement of Richard A. Gonzalez and Glenn F. Tilton from the Board, effective July 1, 2025.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1551152/000110465925047402/0001104659-25-047402-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.